Press Releases

Filter Releases

Date	Title and Summary	View
Toggle SummaryFeb 09, 2017	Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February NEWTOWN, Pa., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar, President & CEO, will present a Company overview	View HTML Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February 16.9 KB
Toggle SummaryJan 27, 2017	Onconova Therapeutics, Inc. to Present at NobleCON13 NEWTOWN, Pa., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Mark Guerin, Chief Financial Officer, will present a company	View HTML Onconova Therapeutics, Inc. to Present at NobleCON13 14.3 KB
Toggle SummaryJan 05, 2017	Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017 NEWTOWN, Pa., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will	View HTML Onconova Therapeutics, Inc. to Present Corporate Overview at Biotech Showcase 2017 13.9 KB
Toggle SummaryDec 06, 2016	Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting Computational Subgroup Analysis of Phase 3 ONTIME Trial Provides Insights into Clinical Response to Rigosertib in Higher-risk MDS	View HTML Onconova and Cellworks Announce Presentation of Rigosertib Predictive Signature for Clinical Response in Myelodysplastic Syndromes (MDS) at 2016 ASH Annual Meeting 19.2 KB
Toggle SummaryDec 05, 2016	Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting --35% Complete Remission (CR) Rate for Combination in 1 st -line Higher-risk MDS Patients-- --Updated Median Duration of Complete Response of 8 Months in All Responding Patients -- NEWTOWN, Pa., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc.	View HTML Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at 2016 ASH Annual Meeting 91.9 KB
Toggle SummaryNov 14, 2016	Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results NEWTOWN, Pa., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the third quarter	View HTML Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2016 Financial Results 38.3 KB
Toggle SummaryNov 04, 2016	Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting --Rigosertib plus Azacitidine Combination Phase 2 Trial Results Featured-- NEWTOWN, Pa., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today	View HTML Onconova Announces Presentations Related to Rigosertib Clinical Studies in Myelodysplastic Syndromes at the 2016 ASH Annual Meeting 18.6 KB
Toggle SummaryOct 13, 2016	Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum NEWTOWN, Pa., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will	View HTML Onconova Therapeutics, Inc. to Present Corporate Update at 2016 BIO Investor Forum 13.8 KB
Toggle SummaryOct 10, 2016	Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City NEWTOWN, Pa., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it will host a Key Opinion Leader lunch discussion on novel	View HTML Onconova to Host Key Opinion Leader Luncheon on Novel Approaches to Targeting the RAS Pathway in Oncology on Monday, October 17, in New York City 18.6 KB
Toggle SummarySep 26, 2016	Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination Pivotal Randomized Trial in 1st-line MDS Patients will Assess Overall Response Rate as Approval Endpoint	View HTML Onconova Announces Successful End-of-Phase 2 Meeting with FDA for Oral Rigosertib and Azacitidine Combination 17.1 KB